Niranjan Kanesa-Thasan - 28 Jul 2021 Form 3 Insider Report for Icosavax, Inc.

Role
Chief Medical Officer
Signature
/s/ Thomas Russo, Attorney-in Fact
Issuer symbol
N/A
Transactions as of
28 Jul 2021
Net transactions value
$0
Form type
3
Filing time
28 Jul 2021, 21:23:51 UTC
Next filing
02 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ICVX Common Stock 120,490 28 Jul 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ICVX Stock Option (Right to Buy) 28 Jul 2021 Common Stock 30,122 $0.8300 Direct F2
holding ICVX Stock Option (Right to Buy) 28 Jul 2021 Common Stock 155,788 $1.04 Direct F3
holding ICVX Stock Option (Right to Buy) 28 Jul 2021 Common Stock 120,316 $5.90 Direct F4
holding ICVX Stock Option (Right to Buy) 28 Jul 2021 Common Stock 124,500 $15.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 53,623 shares subject to repurchase by us, which are subject to vesting.
F2 25% of the shares subject to the option vested on 4/1/2021, and 1/48th of the shares subject to the option vest monthly thereafter.
F3 25% of the shares subject to the option will vest on 1/14/2022, and 1/48th of the shares subject to the option vest monthly thereafter.
F4 25% of the shares subject to the option will vest on 3/19/2022, and 1/48th of the shares subject to the option vest monthly thereafter.
F5 1/48th of the shares subject to the option vest monthly following July 28, 2021, the vesting commencement date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney